Clinical Case Discussion Forum

Subscribe to the Clinical Case Discussion Forum

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Physicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("New Discussion" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM PHYSICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

Outcomes in Children born to Males on Nilotinib

Start
Prev
1
Next
End

Amy Holmes
Topic Author

4 years 8 months ago #1750 by Amy Holmes

Outcomes in Children born to Males on Nilotinib was created by Amy Holmes

I have a 31yo male who is on second line Nilotinib for accelerated phase CML (additional cytogenetic abnormality - derivative chromosome 22). He has now been on Nilotinib for 10 months, with a bcr-abl of 0.49%. Initial CML therapy with imatinib occurred in the Czech republic and was affected by poor compliance. No new mutations were detected at relapse in 2019.

He has been trying to conceive with his 38yo wife for the past 12 months. They are now seeking assisted fertility options. His sperm number and function are reduced by the TKI however it is possible that they will be able to conceive with assistance. Given his wife's age they so not wish to defer pregnancy until his CML is better controlled.

Given the short time he has been on treatment with Nilotinib and the accelerated nature of his disease I have recommended that he remain on therapy however I have been unable to quantify the risk conferred to pregnancy outcomes in this setting. Are you aware of any data on outcomes in children born to males on Nilotinib?

Jane Apperley
Topic Author

4 years 7 months ago - 4 years 7 months ago #1767 by Jane Apperley

Replied by Jane Apperley on topic Outcomes in Children born to Males on Nilotinib

The data relating to men on tyrosine kinase inhibitors who wish to have children is relatively limited, and is better for imatinib, dasatinib and nilotinib than bosutinib and ponatinib
There are two issues, fertility (the ability to conceive) and the potential impact on the child
We do not think the TKI impact male fertility. These data come from animal experiments and the fact that many men have had children while taking TKI. You say that your patients fertility has been affected but do you know it was better at diagnosis?
There is, to date, no suggestion that the TKI taken by men, have any detrimental effect on the foetus or the infant in terms of congenital abnormalities or later development

Jane

Last edit: 4 years 7 months ago by Nicola.

Start
Prev
1
Next
End

Moderators: Nicola, arlene

Copyright © 2023 All Rights Reserved. The iCMLf is registered as charity no. 1132984 in England and Wales
Registered Address: International CML Foundation - 20 Eversley Road - Bexhill-On-Sea, East Sussex, TN40 1HE - UK